The Lancet publication of full Phase 3 data set
In August we were excited to see the full data set from our Phase 3 clinical trial, NefIgArd, published in The Lancet and we are looking forward to a potential full approval of TARPEYO for treatment of IgA Nephropathy, for which the PDUFA date is December 20, 2023.
https://finance.yahoo.com/news/calliditas-interim-report-january-september-063200840.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.